Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Servier Presents Long-Term INDIGO Analyses Demonstrating Sustained Clinical Benefit of VORANIGO® (vorasidenib) in IDH-Mutant Glioma Across Subgroups at SNO 2026

      Servier Pharmaceuticals

      News provided by

      Servier Pharmaceuticals

      Nov 17, 2026, 16:45 ET

      Share this article

      Share this article


      • Extended Phase 3 INDIGO follow-up results, including data from patients who crossed over to VORANIGO® (vorasidenib) from placebo, were presented as an oral presentation on November 14
      • Exploratory INDIGO analysis providing insight into VORANIGO's impact on seizure control and quality of life were presented as an oral presentation on November 15 

      BOSTON, Nov. 17, 2026 /PRNewswire/ -- Servier announced extended follow-up results and subgroup analyses from the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) in mutant isocitrate dehydrogenase 1 or 2 (IDH1/2) glioma who received treatment following surgery as their primary therapy were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia. These analyses provide longer-term insights into VORANIGO's clinical benefit across evaluated subgroups. Alongside these data, an exploratory analysis of seizure activity and quality of life among INDIGO patients was also presented.

      The updated Phase 3 INDIGO results include analyses of 144 of 163 patients randomized to placebo who crossed over to VORANIGO from placebo by the January 17, 2025 data cutoff, along with analyses by histology in oligodendroglioma and astrocytoma. These results build on findings previously reported at ASCO, which demonstrated continued benefit in progression-free survival (PFS) at a median follow-up time of 41.6 months.

      "The results from the INDIGO analyses presented at SNO reinforce the clinical benefit of VORANIGO in patients with Grade 2 IDH-mutant glioma, with the crossover patient population data demonstrating consistent results," said Islam Hassan, M.D., MSc., Global Head of Development, Neuro-Oncology at Servier. "Together with the data on VORANIGO's impact on quality of life, these findings strengthen our understanding of the impact of VORANIGO over time and underscore its important role in glioma care."

      Efficacy data and subgroup analyses after extended follow-up with vorasidenib in INDIGO – a global, randomized, placebo-controlled, double-blinded, Phase 3 trial in grade 2 mutant isocitrate dehydrogenase 1/2 (mIDH1/2) glioma — November 14, 5:00–5:07 p.m. EST

      The latest results from this analysis were presented by Timothy F. Cloughesy, M.D., David Geffen School of Medicine, Department of Neurology, University of California, Los Angeles, an investigator for the INDIGO trial. These data showed clinical benefit among patients who crossed over from placebo and across subgroups defined by histologic subtype. Key findings include:

      • Among patients who crossed over to VORANIGO, median PFS per investigator was 37.2 months overall (95% CI, 33.4-not estimable [NE]). Among patients with astrocytoma who crossed over, median PFS by investigator was 37.2 months (95% CI, 25.6-NE) and in patients with oligodendroglioma who crossed over, median PFS by investigator was not reached (95% CI, 24.6-NE). Median PFS per investigator was 33.4 months (95% CI, 24.6 months-NE) for patients with progressive disease (PD) at crossover and was NE for patients with no PD at crossover.
      • In a post-hoc analysis of patients who crossed over to VORANIGO from placebo, VORANIGO reversed average tumor growth; tumor volume increased on average by 16.1% per six months before crossover and decreased on average by 2.9% per six months after crossover. The shift from growth to shrinkage was observed in both oligodendroglioma and astrocytoma subgroups.
      • The substantial increase in objective response rate (ORR) by blinded independent review committee (BIRC) over time for the overall population (from 10.7% [95% CI, 6.5%–16.4%] in September 2022 to 20.8% [95% CI, 15.0%–27.8%] in January 2025) is reflected in patients with astrocytoma (increase from 7.5% [95% CI, 2.8%–15.6%] to 17.5% [95% CI, 9.9%–27.6%]) as well as those with oligodendroglioma (increased from 13.6% [95% CI, 17.2 %-22.6%] to 23.9% [95%, CI, 15.4%–34.1%]).
      • The safety profile remained consistent with previous data cutoffs with no new safety signals identified during extended follow-up or in crossover patients. Grade >3 treatment-emergent adverse events (TEAEs) occurred in 31.7% of patients randomized to VORANIGO and 20.1% of those crossed over from placebo. The most commonly reported Grade >3 TEAEs were increased alanine aminotransferase (10.8% and 7.6%), increased aspartate aminotransferase (4.8% and 3.5%), seizure (4.8% and 4.2%) and increased gamma-glutamyltransferase (GGT; 3% and 0.7%). There were no treatment-related deaths in either group, and TEAEs leading to discontinuation were uncommon among patients randomized to VORANIGO (4.8%) and those who crossed over from placebo (2.1%).

      "Longer follow-up from INDIGO continues to demonstrate the durable clinical benefit of IDH-inhibition for patients with Grade 2 IDH-mutant glioma across patient subgroups," said Dr. Timothy Cloughesy. "These findings also show promising results in patients who crossed over from placebo, including those whose disease had already progressed, providing further insight into the potential role of IDH inhibition to help manage disease over time."

      Impact of vorasidenib vs placebo on seizure rates and quality of life: exploratory analysis from Phase 3 INDIGO study — November 15, 11:07–11:14 a.m. EST 

      An exploratory analysis presented as an encore by Wolfgang Wick, M.D., Universitätsklinikum Heidelberg & German Cancer Research Center, examined seizure activity and quality of life in INDIGO participants who experienced at least one seizure in the baseline and/or on-treatment periods. At the January 17, 2025, data cutoff:

      • In the overall population of patients treated with VORANIGO, the proportion of patients with on-treatment seizures remained stable from March 2023 to January 2025 (98.1% vs 98.2%). Moreover, the seizure rate with VORANIGO decreased from 18.2 (95% CI, 8.4–39.5) to 15.9 (95% CI, 9.1–27.1) seizures per person-year between March 2023 and January 2025.
        • The rate ratio versus placebo improved from 0.36 (95% CI, 0.14–0.89; P=0.0263) to 0.28 (95% CI, 0.14–0.55; P=0.0002), supporting a sustained treatment effect with longer follow-up.
      • VORANIGO was associated with long-term stabilization of seizure frequency overall and across both oligodendroglioma and astrocytoma. Patients with oligodendroglioma treated with VORANIGO showed a trend towards low, stable seizure counts and patients with astrocytoma experienced low seizure counts regardless of treatment.
      • VORANIGO was associated with sustained preservation of quality of life, with exploratory analyses in patients with >1 seizure, showing a lower risk of worsening versus placebo on the Functional Assessment of Cancer Therapy–Brain (FACT-Br) scale (HR=0.38; 95% CI, 0.15–1.00) and its brain cancer subscale (HR=0.32; 95% CI, 0.11–0.91).

      Media Contact 
      Darby Malkin: [email protected] 

      About Servier in Oncology 
      Servier is a global leader in oncology, governed by a non-profit foundation. Servier approaches innovation with a long-term vision, free of influence from fiduciary responsibilities.

      Servier invests close to 20% of revenue from brand-name medicines in R&D each year. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its progression. Servier believes we can serve more people by helping the right patients find the right treatment, at the right time.

      Servier takes a One Innovation Engine approach to R&D and is actively seeking alliances, partnerships and acquisitions at various stages of the portfolio.

      For more information about working with Servier to bring the promise of tomorrow to the patients it serves, visit Servier.com and Servier.us.

      About Glioma1
      Gliomas are tumors that arise from glial or precursor cells within the central nervous system (CNS). The 2021 World Health Organization (WHO) classification recognizes four general groups of gliomas, one of which is adult-type diffuse gliomas. These diffuse gliomas are the most common primary malignant brain tumors in adults. The pathogenesis and prognosis of these tumors are tightly linked to mutations (or lack thereof) in the metabolic enzyme isocitrate dehydrogenase (IDH), and molecular testing is required for proper diagnosis. As of 2021, adult-type diffuse gliomas are sub-divided into only three categories:

      • Astrocytoma, IDH-mutant (CNS WHO grades 2-4)
      • Oligodendroglioma, IDH-mutant and 1p/19q-codeleted (CNS WHO grades 2-3)
      • Glioblastoma, IDH-wildtype (CNS WHO grade 4)

      VORANIGO IMPORTANT SAFETY INFORMATION

      What is VORANIGO?

      VORANIGO (40 mg tablets) is a prescription medicine used to treat adults and children 12 years of age and older with certain types of Grade 2 brain tumors called astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, following surgery. Your healthcare provider will perform a test to make sure that VORANIGO is right for you. It is not known if VORANIGO is safe and effective in children under 12 years of age. 

      What are the possible side effects of VORANIGO?

      VORANIGO may cause serious side effects, including:

      • Liver problems. Changes in liver function blood tests may happen during treatment with VORANIGO and can be serious. Your healthcare provider will do blood tests to check your liver function before and during treatment with VORANIGO. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems:
      • yellowing of your skin or the white part of your eyes (jaundice)
      • dark tea-colored urine
      • loss of appetite
      • pain on the upper right side of your stomach area
      • feeling very tired or weak

      The most common side effects of VORANIGO include:

      • increased liver enzyme levels in the blood
      • lack of energy, tiredness
      • headache
      • COVID-19
      • muscle aches or stiffness
      • diarrhea
      • nausea
      • seizure

      Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with VORANIGO if you have certain side effects.

      VORANIGO may affect fertility in females and males, which may affect the ability to have children. Talk to your healthcare provider if this is a concern for you.
      These are not all of the possible side effects of VORANIGO.

      Before taking VORANIGO, tell your healthcare provider about all of your medical conditions, including if you:

      • have liver problems
      • have kidney problems or are on dialysis
      • smoke tobacco
      • are pregnant or plan to become pregnant. VORANIGO can harm your unborn baby

      Females who are able to become pregnant:

      • Your healthcare provider will do a pregnancy test before you start treatment with VORANIGO
      • You should use effective nonhormonal birth control during treatment with VORANIGO and for 3 months after the last dose. VORANIGO may affect how hormonal contraceptives (birth control) work and cause them to not work well. Talk to your healthcare provider about birth control methods that may be right for you during treatment with VORANIGO
      • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with VORANIGO

      Males with female partners who are able to become pregnant:

      • You should use effective birth control during treatment with VORANIGO and for 3 months after the last dose
      • Tell your healthcare provider right away if your partner becomes pregnant or thinks she may be pregnant during your treatment with VORANIGO

      Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if VORANIGO passes into breast milk. Do not breastfeed during treatment with VORANIGO and for 2 months after the last dose.

      Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VORANIGO may affect the way other medicines work, and other medicines may affect how VORANIGO works.

      Please click here for full prescribing information.

      Disclosures
      This release contains general information about the Servier Group and its entities (hereinafter "Servier and its Affiliates") and is intended for informational purposes only. The information is thought to be reliable; however, Servier and its Affiliates make no representation as to the accuracy or completeness of the information contained herein or otherwise provided and accept no responsibility or liability, in contract, in tort, in negligence, or otherwise, should the information be found to be inaccurate or incomplete in any respect. 

      Servier and its Affiliates are not acting as an advisor to the recipient of this information, and the ultimate decision to proceed with any transaction rests solely with the recipient of this information. Therefore, prior to entering into any proposed transaction, the recipient of this information should determine, without reliance upon Servier or its Affiliates, the economic risks and merits, as well as the legal, tax, and accounting characterizations and consequences, of the transaction and that it is able to assume these risks. 

      This statement also contains forward-looking statements that are subject to varying levels of uncertainty and risk. Investigational new drugs and indications are subject to further scientific and medical review and regulatory approval. They are not approved for use by the FDA. 

      Any reliance placed on this document is done entirely at the risk of the person placing such reliance. The information contained in this document is neither an offer to sell nor the solicitation of an offer to enter into a transaction. 

      The content of this document is a summary only, is not complete, and does not include all material information about Servier and its Affiliates, including potential conflicts of interest. 

      To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates disclaim all representations, warranties, conditions and guarantees, whether express, implied, statutory or of other kind, nor does it accept any duty to any person, in connection with this document. Without prejudice to the generality of the foregoing, Servier and its Affiliates do not warrant or represent that the information or opinions contained in this document is accurate or complete. 

      To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates shall not be liable for any loss, damage or expense whatsoever, whether direct or indirect, howsoever arising, whether in contract, tort (including negligence), strict liability or otherwise, for direct, indirect, incidental, consequential, punitive or special damages arising out of or in connection with this document, including (without limitation) any course of action taken on the basis of the same. The estimates, strategies, and views expressed in this document are based upon past or current data and information and are subject to change without notice.

      References

      1. Antonelli, M., & Poliani, P. L. (2022). Adult type diffuse gliomas in the new 2021 WHO Classification. Pathologica, 114(6), 397–409. https://doi.org/10.32074/1591-951X-823.

      2. Cloughesy TF, et al. Efficacy data and subgroup analyses after extended follow-up with vorasidenib in INDIGO – a global, randomized, placebo-controlled, double-blinded, Phase 3 trial in grade 2 mutant isocitrate dehydrogenase 1/2 (mIDH1/2) glioma. SNO 2026. [Abstract #CTNI-31].

      3. Wick W, et al. Impact of vorasidenib vs placebo on seizure rates and quality of life: exploratory analysis from Phase 3 INDIGO study. SNO 2026. [Abstract #CTNI-34].

      4. Taylor JW, et al. Real-world utilization and outcomes of vorasidenib-treated patients with grade 2 IDH-mutant gliomas in the US. SNO 2026. [Abstract #NCOG-44].

      5. Komlodi-Pasztor E, et al. Real-world utilization of vorasidenib among patients with grade 3 IDH-mutant gliomas in the US. SNO 2026. [Abstract #NCOG-49].

      6. VORANIGO (vorasidenib) U.S. Prescribing Information. Revised June 2026. Full prescribing information. Accessed October 29, 2026.

      SOURCE Servier Pharmaceuticals

      Modal title

      Also from this source

      Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026

      Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026

      Servier today announced updated four-year results from the Phase 2 FIREFLY-1 study of OJEMDA® (tovorafenib) in patients aged six months to 25 years...

      Servier Highlights Growing Neuro-Oncology Portfolio with New Data Across Pediatric and Adult Glioma at SNO 2026

      Servier Highlights Growing Neuro-Oncology Portfolio with New Data Across Pediatric and Adult Glioma at SNO 2026

      Servier today announced that it will present nine abstracts, including five oral presentations, at the 31st Society for Neuro-Oncology (SNO) Annual...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Biotechnology

      Biotechnology

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.